دورية أكاديمية
أعرض في EDS

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.

التفاصيل البيبلوغرافية
العنوان: CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program.
المؤلفون: Thaventhiran T; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Wong W; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Alghanem AF; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Alhumeed N; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Aljasir MA; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Ramsey S; 2 Inflammation and Remodeling, Pfizer Research Unit, Cambridge, Massachusetts., Sethu S; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Yeang HXA; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Chadwick AE; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Cross M; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Webb SD; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom., Djouhri L; 3 Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia., Ball C; 4 National Institute for Biological Standards and Control, Hertfordshire, United Kingdom., Stebbings R; 4 National Institute for Biological Standards and Control, Hertfordshire, United Kingdom., Sathish JG; 1 Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
المصدر: Monoclonal antibodies in immunodiagnosis and immunotherapy [Monoclon Antib Immunodiagn Immunother] 2019 Apr; Vol. 38 (2), pp. 60-69.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101590955 Publication Model: Print Cited Medium: Internet ISSN: 2167-9436 (Electronic) Linking ISSN: 21679436 NLM ISO Abbreviation: Monoclon Antib Immunodiagn Immunother
أسماء مطبوعة: Original Publication: New Rochelle, NY : Mary Ann Liebert, Inc.
مواضيع طبية MeSH: CD28 Antigens/*immunology , CD4-Positive T-Lymphocytes/*immunology , Glycolysis/*immunology , Lipogenesis/*immunology , Lymphocyte Activation/*immunology , Neoplasms/*metabolism, Acetyl Coenzyme A/metabolism ; Antibodies, Monoclonal/immunology ; CD28 Antigens/metabolism ; Cell Proliferation ; Glucose/metabolism ; Humans ; Immunologic Memory ; Neoplasms/immunology ; Neoplasms/pathology ; Protein Kinases/metabolism ; T-Lymphocytes, Regulatory/immunology ; Tumor Cells, Cultured
مستخلص: CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4 + effector memory T cells (T EMs ) in humans with unwanted serious adverse effects. It is well known that distinct metabolic programs determine the fate and responses of immune cells. In this study, we show that human CD4 + T EMs stimulated with CD28SA adopt a metabolic program similar to those of tumor cells with enhanced glucose utilization, lipid biosynthesis, and proliferation in hypoxic conditions. Identification of metabolic profiles underlying hyperactive T cell activation would provide a platform to test safety of immunostimulatory antibodies.
References: J Neurosci Res. 2000 Apr 15;60(2):150-4. (PMID: 10740219)
Adv Enzymol Relat Areas Mol Biol. 1975;43:57-101. (PMID: 1106128)
Science. 2001 Apr 20;292(5516):504-7. (PMID: 11283355)
Immunity. 2002 Jun;16(6):769-77. (PMID: 12121659)
Cell. 2003 Jul 25;114(2):255-66. (PMID: 12887926)
J Biol Chem. 1959 Oct;234:2544-7. (PMID: 13833535)
Immunol Cell Biol. 1992 Oct;70 ( Pt 5):309-13. (PMID: 1478696)
Oncogene. 2005 Sep 15;24(41):6314-22. (PMID: 16007201)
Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv91-5. (PMID: 16239397)
N Engl J Med. 2006 Sep 7;355(10):1018-28. (PMID: 16908486)
Blood. 2007 Apr 1;109(7):2968-77. (PMID: 17119120)
Biochem Biophys Res Commun. 2007 May 25;357(1):111-7. (PMID: 17400185)
Nat Rev Cancer. 2007 Oct;7(10):763-77. (PMID: 17882277)
J Clin Endocrinol Metab. 2008 Apr;93(4):1433-41. (PMID: 18211970)
PLoS One. 2008 Mar 05;3(3):e1708. (PMID: 18320029)
Biochem J. 2009 Jan 1;417(1):1-13. (PMID: 19061483)
IUBMB Life. 2009 Nov;61(11):1051-62. (PMID: 19859975)
Cell. 2010 Jan 8;140(1):28-30. (PMID: 20085702)
Oncogene. 2010 Aug 5;29(31):4369-77. (PMID: 20514019)
J Immunol. 2011 Mar 15;186(6):3299-303. (PMID: 21317389)
Cold Spring Harb Symp Quant Biol. 2011;76:195-202. (PMID: 21900151)
Immunity. 2012 Jan 27;36(1):68-78. (PMID: 22206904)
J Cell Biochem. 2012 Jul;113(7):2193-200. (PMID: 22388977)
Nat Protoc. 2012 May 10;7(6):1068-85. (PMID: 22576106)
Adv Exp Med Biol. 2012;748:1-11. (PMID: 22729852)
Cancer Res. 2012 Aug 1;72(15):3709-14. (PMID: 22787121)
Curr Opin Oncol. 2012 Nov;24(6):650-4. (PMID: 22913968)
World J Biol Chem. 2012 Aug 26;3(8):167-74. (PMID: 22937213)
J Hematol Oncol. 2013 Feb 25;6:19. (PMID: 23442817)
Immunity. 2013 Apr 18;38(4):633-43. (PMID: 23601682)
PLoS One. 2013 Apr 19;8(4):e61262. (PMID: 23620736)
Br J Clin Pharmacol. 2013 Aug;76(2):299-315. (PMID: 23701319)
Nat Commun. 2013;4:2236. (PMID: 23900562)
Dis Model Mech. 2013 Nov;6(6):1353-63. (PMID: 24203995)
Eur J Immunol. 2014 Apr;44(4):1225-36. (PMID: 24374661)
Cell Metab. 2014 Jul 1;20(1):61-72. (PMID: 24930970)
Immunity. 2014 Jul 17;41(1):75-88. (PMID: 25001241)
MAbs. 2014;6(5):1290-9. (PMID: 25517314)
Trends Immunol. 2015 Feb;36(2):71-80. (PMID: 25601541)
J Immunol Methods. 2015 Sep;424:43-52. (PMID: 25960173)
J Exp Med. 2015 Aug 24;212(9):1345-60. (PMID: 26261266)
Cell Metab. 2017 Jul 5;26(1):94-109. (PMID: 28683298)
Nat Rev Immunol. 2018 Jan;18(1):19-34. (PMID: 28944771)
Trends Mol Med. 2018 Jan;24(1):30-48. (PMID: 29246759)
Cell Rep. 2018 Feb 6;22(6):1509-1521. (PMID: 29425506)
Front Oncol. 2018 Aug 03;8:237. (PMID: 30123774)
J Biol Chem. 1979 Apr 25;254(8):2669-76. (PMID: 429309)
Biochem Biophys Res Commun. 1983 Dec 16;117(2):435-43. (PMID: 6140922)
J Biol Chem. 1983 Apr 25;258(8):4950-6. (PMID: 6300106)
Proc Nutr Soc. 1983 Jun;42(2):263-71. (PMID: 6351084)
معلومات مُعتمدة: MR/L006758/1 United Kingdom MRC_ Medical Research Council
فهرسة مساهمة: Keywords: CD28 superagonist; CD4 effector memory T cells; glycolysis; lipogenesis; oxidative phosphorylation
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (CD28 Antigens)
72-89-9 (Acetyl Coenzyme A)
EC 2.7.- (Protein Kinases)
EC 2.7.1.- (ATP-citrate lyase kinase)
IY9XDZ35W2 (Glucose)
تواريخ الأحداث: Date Created: 20190423 Date Completed: 20190812 Latest Revision: 20210109
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6634261
DOI: 10.1089/mab.2018.0042
PMID: 31009338
قاعدة البيانات: MEDLINE
الوصف
تدمد:2167-9436
DOI:10.1089/mab.2018.0042